Microbix Biosystems Inc
TSX:MBX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.21
0.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CA |
|
Microbix Biosystems Inc
TSX:MBX
|
30m CAD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
387B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
174.7B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 710 029.9% |
| 30th Percentile | -65.8% |
| Median | -2.4% |
| 70th Percentile | 11% |
| Max | 71 100% |
Other Profitability Ratios
Microbix Biosystems Inc
Glance View
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm manufactures a range of biological materials for the diagnostics industry, notably antigens (Antigen business) used in immunoassays and its quality assessment and proficiency testing controls (QAPs business). The firm operates in two segments: the development, manufacturing, and sales of antigens as materials for the medical diagnostic industry or as quality assessment products (as finished products) and viral transport medium (VTM) and the development and commercialization of products or technologies such as Kinlytic and . The Kinlyti urokinase, which is a biologic thrombolytic drug used to treat blood clots. The firm's catalogue of catalogue covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually transmitted and insect-borne diseases. Its QAPs are available in over 30 countries.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Microbix Biosystems Inc is -8.5%, which is below its 3-year median of 3.9%.
Over the last 3 years, Microbix Biosystems Inc’s Operating Margin has decreased from 13.7% to -8.5%. During this period, it reached a low of -16.6% on Sep 30, 2023 and a high of 18.7% on Mar 31, 2024.